INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $501,000 | +67.6% | 27,000 | 0.0% | 0.00% | – |
| Q2 2023 | $299,000 | -96.8% | 27,000 | -96.1% | 0.00% | -100.0% |
| Q1 2023 | $9,217,000 | +10.9% | 686,267 | +2.1% | 0.01% | +10.0% |
| Q4 2022 | $8,313,000 | -9.2% | 671,995 | +2.4% | 0.01% | -9.1% |
| Q3 2022 | $9,159,000 | +2.8% | 655,940 | +1.7% | 0.01% | +10.0% |
| Q2 2022 | $8,909,000 | -11.8% | 645,069 | +3.9% | 0.01% | +25.0% |
| Q1 2022 | $10,098,000 | +0.4% | 620,671 | +0.5% | 0.01% | 0.0% |
| Q4 2021 | $10,059,000 | +9.0% | 617,497 | -0.6% | 0.01% | 0.0% |
| Q3 2021 | $9,228,000 | -31.7% | 621,412 | -8.1% | 0.01% | -27.3% |
| Q2 2021 | $13,504,000 | -12.1% | 676,210 | +1.6% | 0.01% | -50.0% |
| Q1 2021 | $15,365,000 | -11.7% | 665,762 | -5.5% | 0.02% | -12.0% |
| Q4 2020 | $17,406,000 | -46.1% | 704,684 | -9.5% | 0.02% | -54.5% |
| Q3 2020 | $32,296,000 | -12.2% | 778,959 | +1.4% | 0.06% | -12.7% |
| Q2 2020 | $36,797,000 | -18.3% | 768,044 | +7.4% | 0.06% | -32.3% |
| Q1 2020 | $45,030,000 | -33.4% | 715,214 | +31.1% | 0.09% | -3.1% |
| Q4 2019 | $67,588,000 | +181.1% | 545,414 | +50.5% | 0.10% | +140.0% |
| Q3 2019 | $24,045,000 | +155.8% | 362,342 | +206.8% | 0.04% | +700.0% |
| Q2 2019 | $9,399,000 | +125.3% | 118,113 | +216.8% | 0.01% | -28.6% |
| Q1 2019 | $4,171,000 | +13.3% | 37,285 | +2.1% | 0.01% | 0.0% |
| Q4 2018 | $3,682,000 | -18.1% | 36,527 | +2.7% | 0.01% | 0.0% |
| Q3 2018 | $4,493,000 | +289.7% | 35,561 | +158.8% | 0.01% | +250.0% |
| Q2 2018 | $1,153,000 | +93.5% | 13,742 | +42.0% | 0.00% | +100.0% |
| Q1 2018 | $596,000 | +4.4% | 9,680 | -0.9% | 0.00% | 0.0% |
| Q4 2017 | $571,000 | +96.9% | 9,768 | +95.4% | 0.00% | 0.0% |
| Q3 2017 | $290,000 | -99.0% | 5,000 | -97.9% | 0.00% | -98.1% |
| Q2 2017 | $28,746,000 | +5.2% | 237,431 | -1.7% | 0.05% | +6.0% |
| Q1 2017 | $27,321,000 | +60.6% | 241,565 | +54.2% | 0.05% | +51.5% |
| Q4 2016 | $17,016,000 | -71.8% | 156,611 | -57.3% | 0.03% | -71.6% |
| Q3 2016 | $60,308,000 | +831.5% | 366,412 | +707.4% | 0.12% | +1833.3% |
| Q2 2016 | $6,474,000 | +409.0% | 45,380 | +358.3% | 0.01% | +100.0% |
| Q1 2016 | $1,272,000 | +118.9% | 9,902 | +154.6% | 0.00% | +200.0% |
| Q4 2015 | $581,000 | -79.9% | 3,890 | -77.6% | 0.00% | -83.3% |
| Q3 2015 | $2,887,000 | -42.6% | 17,404 | -16.5% | 0.01% | -40.0% |
| Q2 2015 | $5,033,000 | -7.3% | 20,850 | +8.3% | 0.01% | -9.1% |
| Q1 2015 | $5,429,000 | +239.5% | 19,250 | +87.8% | 0.01% | +266.7% |
| Q4 2014 | $1,599,000 | -42.3% | 10,250 | -12.4% | 0.00% | -50.0% |
| Q3 2014 | $2,769,000 | -2.9% | 11,700 | -2.9% | 0.01% | 0.0% |
| Q2 2014 | $2,851,000 | +33.0% | 12,050 | +85.4% | 0.01% | +50.0% |
| Q1 2014 | $2,144,000 | – | 6,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |